Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Trinity Biotech (TRIB) EBIAT (2016 - 2024)

Trinity Biotech's EBIAT history spans 16 years, with the latest figure at -$17.0 million for Q4 2024.

  • On a quarterly basis, EBIAT fell 208.16% to -$17.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$31.8 million, a 7370.19% decrease, with the full-year FY2025 number at -$2.3 million, up 92.65% from a year prior.
  • EBIAT hit -$17.0 million in Q4 2024 for Trinity Biotech, down from -$4.8 million in the prior quarter.
  • Over the last five years, EBIAT for TRIB hit a ceiling of $11.8 million in Q2 2023 and a floor of -$17.0 million in Q4 2024.
  • Historically, EBIAT has averaged -$3.8 million across 5 years, with a median of -$3.5 million in 2020.
  • Biggest five-year swings in EBIAT: skyrocketed 297.7% in 2021 and later crashed 2026.0% in 2022.
  • Tracing TRIB's EBIAT over 5 years: stood at -$10.0 million in 2020, then soared by 87.38% to -$1.3 million in 2021, then tumbled by 696.84% to -$10.1 million in 2022, then soared by 45.42% to -$5.5 million in 2023, then tumbled by 208.16% to -$17.0 million in 2024.
  • Business Quant data shows EBIAT for TRIB at -$17.0 million in Q4 2024, -$4.8 million in Q3 2024, and -$10.1 million in Q2 2024.